Anavex Life Sciences Q2 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate, Cash and Equivalents of $139.4M
Anavex Life Sciences Q2 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate, Cash and Equivalents of $139.4M
Anavex Life Sciences 2024年第二季度GAAP每股收益（0.13）未達到預期（0.11）美元，現金及等價物爲1.394億美元
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 176.47 percent decrease over earnings of $0.17 per share from the same period last year.
Anavex Life Sciences（納斯達克股票代碼：AVXL）公佈的季度虧損爲每股0.13美元，比分析師普遍預期的0.11美元（0.11美元）低18.18％。與去年同期的每股收益0.17美元相比，下降了176.47％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。